Healthcare - Medical - Devices - NASDAQ - US
$ 2.71
-3.56 %
$ 8.5 M
Market Cap
-0.1
P/E
Tenon Medical, Inc., a medical device company, develops surgical implant systems to optimize sacroiliac joint fixation/fusion surgery and corresponding outcomes. It sells The CATAMARAN SIJ Fusion System that includes instruments and implants designed to prepare and fixate the SI-Joint for fusion in the United States and Puerto Rico. The company was founded in 2012 and is based in Los Gatos, California.[ Read More ]
The intrinsic value of one TNON stock under the base case scenario is HIDDEN Compared to the current market price of 2.71 USD, Tenon Medical, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart TNON
FINANCIALS
2.93 M
REVENUE
-15.7 M
OPERATING INCOME
-15.6 M
NET INCOME
-12.2 M
OPERATING CASH FLOW
6.14 M
INVESTING CASH FLOW
6.3 M
FINANCING CASH FLOW
887 K
REVENUE
-3.22 M
OPERATING INCOME
-3.18 M
NET INCOME
-2.34 M
OPERATING CASH FLOW
-104 K
INVESTING CASH FLOW
9.64 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Tenon Medical, Inc.
| Current Assets | 3.89 M |
| Cash & Short-Term Investments | 2.43 M |
| Receivables | 518 K |
| Other Current Assets | 943 K |
| Non-Current Assets | 2.46 M |
| Long-Term Investments | 0 |
| PP&E | 1.61 M |
| Other Non-Current Assets | 849 K |
| Current Liabilities | 3.14 M |
| Accounts Payable | 433 K |
| Short-Term Debt | 1.43 M |
| Other Current Liabilities | 1.28 M |
| Non-Current Liabilities | 2.43 M |
| Long-Term Debt | 428 K |
| Other Non-Current Liabilities | 2 M |
EFFICIENCY
Earnings Waterfall
Tenon Medical, Inc.
| Revenue | 2.93 M |
| Cost Of Revenue | 1.69 M |
| Gross Profit | 1.24 M |
| Operating Expenses | 17 M |
| Operating Income | -15.7 M |
| Other Expenses | -146 K |
| Net Income | -15.6 M |
RATIOS
42.38%
GROSS MARGIN
-537.12%
OPERATING MARGIN
-532.14%
NET MARGIN
-2002.70%
ROE
-245.56%
ROA
-806.10%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Tenon Medical, Inc.
| Net Income | -15.6 M |
| Depreciation & Amortization | 426 K |
| Capital Expenditures | -361 K |
| Stock-Based Compensation | 4.14 M |
| Change in Working Capital | -1.17 M |
| Others | -627 K |
| Free Cash Flow | -12.5 M |
Wall Street Analysts Price Targets
Tenon Medical, Inc.
TNON has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Tenon Medical, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Jun 14, 2023
|
Bought 13.7 K USD
|
VAN DICK STEVEN M
Chief Financial Officer |
+ 50000
|
0.273 USD |
|
1 year ago
May 23, 2023
|
Sell 35 K USD
|
FOSTER STEVEN M
CEO and President |
- 27791
|
1.26 USD |
|
1 year ago
May 23, 2023
|
Sell 81.9 K USD
|
GINN RICHARD
Chief Technology Officer |
- 64990
|
1.26 USD |
7. News
Tenon Medical, Inc. (TNON) Q3 2024 Earnings Call Transcript
Tenon Medical, Inc. (NASDAQ:TNON ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Steven Foster - President & CEO Kevin Williamson - CFO Conference Call Participants Anthony Vendetti - Maxim Group Operator Greetings, and welcome to the Tenon Medical Third Quarter 2024 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded.
seekingalpha.com
- 3 days ago
Tenon Medical Reports Third Quarter 2024 Financial Results
~ 3Q Revenue of $0.9 Million, Consistent with Prior Quarter; Year to Date Revenue of $2.5 Million, Growth of 18.3% Compared to Prior Year ~ ~ Published Interim Analysis from MAINSAIL™ Study; Post-Market Study Supports the Safety and Efficacy of the Catamaran SI Joint Fusion System® Including Radiographic Proof of Fusion ~ ~ Initial Clinical Procedures Completed with New Catamaran SE Platform ~ ~ Granted Issuance of Three U.S. Patents ~ ~ Received Net Proceeds of ~$9.6 Million from Equity Financing Transactions ~ LOS GATOS, CA / ACCESSWIRE / November 13, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Subsequent Highlights Revenue of $0.9 Million in the third quarter of 2024, a 1.6% decrease over the second quarter of 2024.
accesswire.com
- 3 days ago
Tenon Medical, Inc. Announces Timing of Third Quarter 2024 Financial Results
LOS GATOS, CA / ACCESSWIRE / October 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release financial results for the third quarter 2024 ended September 30, 2024 after market close on Wednesday, November 13, 2024. The Company will also hold a conference call the same day at 4:30 p.m.
accesswire.com
- 2 weeks ago
Tenon Medical(R) Regains Full Compliance with Nasdaq Continued Listing Requirements
LOS GATOS, CA / ACCESSWIRE / October 28, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that it is in compliance with all relevant Nasdaq continued listing Rules. The Company had previously reported non compliance with Nasdaq Rules 5605(b)(1), 5605(c)(2) and 5605(d)(2), with respect to the number of independent directors on its board of directors and certain board committees; Nasdaq Rule 5550(a)(2), with respect to its minimum bid price; Nasdaq Rule 5550(a)(4), with respect to number of shares in its public float; and Nasdaq Rule 5550(b), with respect to its stockholders' equity.
accesswire.com
- 2 weeks ago
Tenon Medical(R) Announces Issuance of Three U.S. Patents
Further Solidifies International Patent Portfolio and Underscores the Company's Commitment to Innovation of SI Joint Stabilization Systems and Methods LOS GATOS, CA / ACCESSWIRE / October 17, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the issuance of U.S. Patent Nos. 12,115,075, 12,115,076 and 12,115,077.
accesswire.com
- 1 month ago
Tenon Medical Announces Issuance of Three Notices of Allowance for Patent Applications from the USPTO
Tenon Now Holds 9 Granted Patents and 26 Pending Applications for the Catamaran® SI Joint Fusion System Worldwide LOS GATOS, CA / ACCESSWIRE / September 19, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the United States Patent and Trademark Office ("USPTO") issued three (3) Notices of Allowance for U.S. Patent Application Numbers 17,469,132 and 17/468,811, both entitled "Sacroiliac Joint Stabilization Prostheses", and 18/612,032, entitled "Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints". The U.S. patents based on the applications should thus issue within the next ninety (90) days.
accesswire.com
- 1 month ago
Tenon Medical, Inc. Announces Closing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
LOS GATOS, CA / ACCESSWIRE / September 17, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced the closing of its previously announced "reasonable best efforts" public offering with a single health-care focused institutional investor for the purchase and sale of 1,222,850 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,222,850 shares of common stock at a combined offering price of $3.68 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the "Offering"). The Company received aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and other offering expenses.
accesswire.com
- 1 month ago
Tenon Medical, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
LOS GATOS, CA / ACCESSWIRE / September 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced the pricing of its "reasonable best efforts" public offering with a single health-care focused institutional investor for the purchase and sale of up to 1,222,850 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,222,850 shares of common stock at a combined offering price of $3.68 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the "Offering"). The Company expects to receive aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants.
accesswire.com
- 2 months ago
Tenon(R) Medical Announces the Introduction of the Catamaran(R) SE SI Joint Fusion System
~ New SI Joint Fixation Device Offers a 30% Reduction in Implant Size Providing Physicians Choices for Varying Anatomy and Treatment Strategies with the Catamaran Technology ~ ~ The SE System Can Also Be Utilized with a Manual Drilling Option During Implant Preparation~ LOS GATOS, CA / ACCESSWIRE / September 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced preparation for the initial alpha launch of the Company's new Catamaran SE SI Joint Fusion System targeted for the beginning of Q4. The Catamaran SE Fixation Device extends the line of implant offerings for physicians preferring a smaller Catamaran implant when performing a SI joint fusion procedure.
accesswire.com
- 2 months ago
Tenon(R) Medical Announces First Peer Reviewed Publication of the MAINSAIL(TM) Study Analyzing the First 33 Consecutive Patients from an IRB Approved, Prospective, Multi-Centered, Post-Market Clinical Investigation Utilizing the Catamaran(R) SI Joint Fusion System
~ Interim Patient Outcomes Demonstrate Significant Improvements in Pain (VAS) and Disability (ODI), Along with High Patient Satisfaction and Safety Profile at Primary 6-month Analysis ~ ~ Preliminary SI Joint Fusion Results Based on Independent Radiologist Review Indicate Evidence of Fusion at 12-Months Post-Procedure ~ LOS GATOS, CA / ACCESSWIRE / September 4, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain Sacroiliac Joint (SIJ) disorders, today announced the first publication of the Catamaran SI Joint Fusion System® MAINSAIL™ study. This study is an ongoing prospective, single-arm, multi-center, post-market study evaluating clinical and radiographic outcomes of adult patients with sacroiliac joint disruptions or degenerative sacroiliitis treated with the Catamaran SI Joint Fusion System.
accesswire.com
- 2 months ago
Tenon Medical Announces 1:8 Reverse Split
LOS GATOS, CA / ACCESSWIRE / September 4, 2024 / Tenon Medical, Inc. ("Tenon" or the "Company") (NASDAQ:TNON), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced, a 1:8 reverse stock split of the Company's issued and outstanding common stock. The reverse stock split will become effective at 12:01, Eastern Time, on September 6, 2024, prior to the commencement of trading on the Nasdaq Capital Market.
accesswire.com
- 2 months ago
Tenon(R) Medical Announces First Peer Reviewed Publication of the MAINSAIL(TM) Study Analyzing the First 33 Consecutive Patients from an IRB Approved, Prospective, Multi-Centered, Post-Market Clinical Investigation Utilizing the Catamaran(R) SI Joint Fusion System
~ Interim Patient Outcomes Demonstrate Significant Improvements in Pain (VAS) and Disability (ODI), Along with High Patient Satisfaction and Safety Profile at Primary 6-month Analysis ~ ~ Preliminary SI Joint Fusion Results Based on Independent Radiologist Review Indicate Evidence of Fusion at 12-Months Post-Procedure ~ LOS GATOS, CA / ACCESSWIRE / September 4, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain Sacroiliac Joint (SIJ) disorders, today announced the first publication of the Catamaran SI Joint Fusion System® MAINSAIL™ study. This study is an ongoing prospective, single-arm, multi-center, post-market study evaluating clinical and radiographic outcomes of adult patients with sacroiliac joint disruptions or degenerative sacroiliitis treated with the Catamaran SI Joint Fusion System.
accesswire.com
- 2 months ago
8. Profile Summary
Tenon Medical, Inc. TNON
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 8.5 M
Dividend Yield
0.00%
Description
Tenon Medical, Inc., a medical device company, develops surgical implant systems to optimize sacroiliac joint fixation/fusion surgery and corresponding outcomes. It sells The CATAMARAN SIJ Fusion System that includes instruments and implants designed to prepare and fixate the SI-Joint for fusion in the United States and Puerto Rico. The company was founded in 2012 and is based in Los Gatos, California.
Contact
104 Cooper Court, Los Gatos, CA, 95032
https://www.tenonmed.com
IPO Date
April 27, 2022
Employees
21
Officers
Mr. Steven M. Foster
Chief Executive Officer, President & Director
Mr. Richard Ginn
Founder, Chief Technology Officer & Director
Mr. Richard M. Ferrari
Founder & Executive Chairman
Mr. Kevin Williamson
Chief Financial Officer